ArticleFrontiers in immunology2025
Interleukin-10 as a potential biomarker reflecting the multidimensional pathological network in patients with severe fever with thrombocytopenia syndrome: viral load, cytokine storm, organ damage, and immune suppression.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Standardized LDH-to-lymphocyte ratio improves early mortality prediction in severe fever with thrombocytopenia syndrome: A 15-day competing-risk bedside model.PLoS neglected tropical diseases · 2026Article
- Antibodies against interleukin-10 receptor reduce IL-6 and TNF-α levels and increase TGF-β levels in patients with severe fever with thrombocytopenia syndrome virus and SARS-CoV-2 infection.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is a highly fatal infectious disease, potentially driven by cytokine storms. This study evaluates plasma interleukin-10 (IL-10) as a prognostic biomarker by analyzing its association with disease severity and outcomes, aiming to improve early risk stratification and clinical management. Methods: A retrospective study was conducted on SFTS admitted to Yantai Infectious Disease Hospital from 2022 to 2024. Patients were grouped into survivors (n=160) and non-survivors (n=55). Clinical data from the first 24 hours of admission were collected. To determine independent risk factors influencing prognosis, logistic regression analysis was utilized, particularly assessing the clinical predictive significance of IL-10. Results: This investigation assessed 215 SFTS patients, where 160 were placed in the survival category and 55 in the mortality category. Multivariate analysis identified IL-10 as an independent predictor of mortality in individuals with SFTS. Receiver Operating Characteristic curve analysis indicated that IL-10 possessed a strong predictive capability for patient mortality, achieving an area under the curve (AUC) of 0.8044 (95% Conclusion: Plasma IL-10 is an early prognostic biomarker for SFTS, with serial monitoring guiding clinical decisions to improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.